tyrosine kinase inhibitor - Globe Thesis

Keyword [tyrosine kinase inhibitor] Result: 141 - 160 \| Page: 8 of 10
141.	Administration Of TKI Maintenance After Allogeneic Stem Cell Transplantation In Ph+ALL Patients
142.	The Research Of Clinical Characteristic And Prognosis Among Young Patients With Non-small-cell Lung Cancer
143.	Sequential Treatment Of EGFR Tyrosine Kinase Inhibitors And Platinum Doublet Chemotherapy On Survival Of Advanced Non-small-cell Lung Cancer With EGFR Mutations
144.	Study On The Effects And Molecular Mechanisms Underlying The Induced Differertiation Therapy Of Acute Myeloid Leukemia With A Natural Product Vibsanin A Combined With Tyrosine Kinase Targeted Drugs
145.	Study On The Role Of Traditional Chinese Medicine Or Its Derivative In The Treatment Of Hematological Malignancies And The Associated Molecular Mechanisms
146.	The Impact Of Epidermal Growth Factor Receptor Mutation On The Treatment Strategy And Outcomes Of Patients With Non-small Cell Lung Cancer
147.	Molecular Mechanisms Of Tyrosine Kinase Inhibitor Resistance Induced By Cytoplasmic/Nuclear Translocation Of Epidermal Growth Factor Receptor
148.	Clinical Studies And Prognostic Analysis Of Leptomeningeal Metastases From Lung Cancer And Adenosquamous Lung Carcinoma
149.	Correlation Between Tyrosine Kinase Inhibitor Therapy And Radiotherapy Induced Radiation Pneumonitis In Patients With Advanced Non-small Cell Lung Cancer
150.	Establishment Of Third Generation EGFR-TKI Osimertinib Acquired Resistant NSCLC Cell Line And Preliminary Study On Resistance Mechanism
151.	Tumor Microenvironment-related Factors On NSCLC Resistance To EGFR-tyrosine Kinase Inhibitor Gefitinib And The Underlying Mechanism
152.	The Role Of Local Ablation Thepray For Advanced EGFR-mutant NSCLC Patients With Oligometastatic Disease Or Oligoprogressive Disease
153.	Cytoplasmic P120ctn Promotes Tyrosine Kinase Inhibitor Resistance In Lung Cancer Cells By Activating PAKs And Mediated EGFR Downstream Activation
154.	The Role And Mechanism Of HSP70 In The Acquired Resistance Of EGFR-TKI-sensitive Non-small Cell Lung Cancer
155.	The Effect And Clinical Significance Of The Second Generation Of TKI Drug Dasatinib On The Lymphocyte Subsets In CML Patients
156.	The Role Of Rerum VEGF In Determining EGFR-TKI Acquired Resistance In Lung Adenocarcinoma
157.	Serum Albumin And CEA Are Associated With Prognosis Of EGFR-TKI Treatment In Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
158.	Efficacy Of Lenvatinib On Choroidal Neovascularization-a Multitargeted Tyrosine Kinase Inhibitor
159.	Evaluation Of Targeted Efficacy By MSCT Manifestations In EGFR-mutated Peripheral Lung Adenocarcinoma
160.	Clinical And Biological Study On Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
<<First <Prev Next> Last>> Jump to